ZA954099B - Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders - Google Patents

Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders

Info

Publication number
ZA954099B
ZA954099B ZA954099A ZA954099A ZA954099B ZA 954099 B ZA954099 B ZA 954099B ZA 954099 A ZA954099 A ZA 954099A ZA 954099 A ZA954099 A ZA 954099A ZA 954099 B ZA954099 B ZA 954099B
Authority
ZA
South Africa
Prior art keywords
substances
tumors
combination
necrosis
necroses
Prior art date
Application number
ZA954099A
Other languages
English (en)
Inventor
Klaus Bosslet
Joerg Czech
Dieter Hoffman
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of ZA954099B publication Critical patent/ZA954099B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA954099A 1994-05-20 1995-05-19 Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders ZA954099B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4417865A DE4417865A1 (de) 1994-05-20 1994-05-20 Kombination von Tumornekrose-induzierenden Substanzen mit Substanzen, die durch Nekrosen aktiviert werden, zur selektiven Tumortherapie

Publications (1)

Publication Number Publication Date
ZA954099B true ZA954099B (en) 1996-01-19

Family

ID=6518684

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA954099A ZA954099B (en) 1994-05-20 1995-05-19 Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders

Country Status (14)

Country Link
US (1) US5710134A (da)
EP (1) EP0696456B1 (da)
JP (1) JP4576005B2 (da)
KR (1) KR100386492B1 (da)
AT (1) ATE199645T1 (da)
AU (1) AU2015195A (da)
CA (1) CA2149818C (da)
DE (2) DE4417865A1 (da)
DK (1) DK0696456T3 (da)
ES (1) ES2154693T3 (da)
GR (1) GR3035593T3 (da)
NZ (1) NZ272150A (da)
PT (1) PT696456E (da)
ZA (1) ZA954099B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
GB9610967D0 (en) 1996-05-24 1996-07-31 Cambridge Antibody Tech Specific binding members,materials and methods
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US20030045681A1 (en) * 1998-05-11 2003-03-06 Anthony J. Zelano Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
CA2333147C (en) 1998-07-13 2012-02-07 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
US10973397B2 (en) 1999-03-01 2021-04-13 West View Research, Llc Computerized information collection and processing apparatus
US8636648B2 (en) * 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
JP2003524624A (ja) * 1999-04-09 2003-08-19 ジェシー エル エス オウ 治療薬の組織への送達を高める方法及び組成物
JP2003524018A (ja) * 2000-02-24 2003-08-12 アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ フィブロネクチンのｅｄ‐ｂドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用
CN1246333C (zh) * 2000-09-07 2006-03-22 舍林股份公司 EDb－纤粘连蛋白结构域(II)的受体
US20040247597A1 (en) * 2001-06-20 2004-12-09 Peter Carmeliet Method of treating atherosclerosis and other inflammatory diseases
US20050026220A1 (en) * 2001-08-10 2005-02-03 Shahin Rafii Isolation and mobilization of stem cells expressing vegfr-1
KR20120068769A (ko) 2002-07-15 2012-06-27 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 음이온성 인지질 및 아미노인지질에 결합하는 선택된 항체 및 치료하는데 있어서 이의 용도
KR101395370B1 (ko) 2004-01-22 2014-05-14 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
US20050266067A1 (en) * 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
JP4636020B2 (ja) * 2004-05-26 2011-02-23 株式会社ニコン 波長変換光学系、レーザ光源、露光装置、マスク検査装置、及び高分子結晶の加工装置
CN101102791B (zh) * 2004-11-18 2011-12-14 英克隆有限责任公司 抗血管内皮生长因子受体-1的抗体
WO2006099445A2 (en) * 2005-03-14 2006-09-21 Massachusetts Institute Of Technology Nanocells for diagnosis and treatment of diseases and disorders
US8426387B2 (en) * 2006-03-31 2013-04-23 Stephen Carper Treatments for cancer
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
CA2705152C (en) 2007-11-09 2016-10-11 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
US8253725B2 (en) * 2007-12-28 2012-08-28 St. Jude Medical, Atrial Fibrillation Division, Inc. Method and system for generating surface models of geometric structures

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU33730B (en) * 1967-04-18 1978-02-28 Farmaceutici Italia Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en) * 1976-01-15 1977-03-15 Stanford Research Institute Synthesis of adriamycin and 7,9-epiadriamycin
US5098702A (en) * 1986-04-09 1992-03-24 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
GB8705780D0 (en) * 1987-03-11 1987-04-15 Norsk Hydro As Anticancer compounds
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121
WO1992017151A2 (en) * 1991-03-27 1992-10-15 Lankenau Medical Research Center Method of administering drugs through modification of epithelial tight junctions by tumor necrosis factor
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
DE4236237A1 (de) * 1992-10-27 1994-04-28 Behringwerke Ag Prodrugs, ihre Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
AU2015195A (en) 1995-11-30
CA2149818A1 (en) 1995-11-21
JPH07316074A (ja) 1995-12-05
US5710134A (en) 1998-01-20
NZ272150A (en) 1997-04-24
CA2149818C (en) 2010-03-23
DE59509088D1 (de) 2001-04-19
EP0696456A2 (de) 1996-02-14
ATE199645T1 (de) 2001-03-15
JP4576005B2 (ja) 2010-11-04
DE4417865A1 (de) 1995-11-23
EP0696456A3 (de) 1998-10-28
DK0696456T3 (da) 2001-06-25
PT696456E (pt) 2001-07-31
KR950031106A (ko) 1995-12-18
GR3035593T3 (en) 2001-06-29
KR100386492B1 (ko) 2003-08-14
EP0696456B1 (de) 2001-03-14
ES2154693T3 (es) 2001-04-16

Similar Documents

Publication Publication Date Title
ZA954099B (en) Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
FI961976A0 (fi) Peptidyyliyhdisteitä ja niiden terapeuttinen käyttö metalloproteinaasien inhibiittoreina
DE69905368D1 (en) Oxydiertes thymosin beta 4
WO1997044063A3 (en) Dha-pharmaceutical agent conjugates
ATE324119T1 (de) Verwendung von saccharid-konjugaten
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
BG101290A (en) New promedicaments for the therapy of tumours and inflammatory diseases
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
NO972391D0 (no) 2-substituerte 1,2,5-tiadiazolidin-3-on 1,1-dioksider og preparater og metoder for anvendelse derav
BG102106A (en) Phermaceutical composition containing proteinase inhibitor and monoglyceride
GR3034575T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
NZ333232A (en) Use of p-aminophenol derivatives (paracetamol) to treat neurodegenerative disease
NZ309171A (en) use of apoptin as an antitumour agent which specifically kills tumour and not normal cells
IL114382A (en) Lymphotoxin for use as a medicament for cancer therapy and use thereof in the manufacture of such medicament
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
WO2001041747A3 (de) Pharmazeutische zubeteitung enthaltend zytostatika und electronenakzeptoren zur behandlung von krebs
AU2921999A (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use
DE69700983D1 (de) Ligandgerichtete enzyme-prodrug therapie
WO2001009165A8 (en) ACTIVATION OF PEPTIDE PRODRUGS BY hK2
TR199701605A2 (xx) S�lfonamid-substit�e edilmi� bile�ikler
AU5434899A (en) Cancer treatment
PT874630E (pt) Terapia combinada de um inibidor da topoisomerase ii e um derivado da bis-dioxipiperazina
Bach Lonazolac-Ca(Irritren), a new non-steroidal antirheumatic agent. Clinical data based on 18, 000 treated patients.